1. Home
  2. DALN vs PTN Comparison

DALN vs PTN Comparison

Compare DALN & PTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DALN
  • PTN
  • Stock Information
  • Founded
  • DALN 1954
  • PTN 1986
  • Country
  • DALN United States
  • PTN United States
  • Employees
  • DALN N/A
  • PTN N/A
  • Industry
  • DALN Newspapers/Magazines
  • PTN Biotechnology: Pharmaceutical Preparations
  • Sector
  • DALN Consumer Discretionary
  • PTN Health Care
  • Exchange
  • DALN Nasdaq
  • PTN Nasdaq
  • Market Cap
  • DALN 24.6M
  • PTN 25.4M
  • IPO Year
  • DALN 2008
  • PTN 1993
  • Fundamental
  • Price
  • DALN $6.64
  • PTN $0.98
  • Analyst Decision
  • DALN
  • PTN Strong Buy
  • Analyst Count
  • DALN 0
  • PTN 1
  • Target Price
  • DALN N/A
  • PTN $17.00
  • AVG Volume (30 Days)
  • DALN 79.0K
  • PTN 573.0K
  • Earning Date
  • DALN 11-12-2024
  • PTN 02-13-2025
  • Dividend Yield
  • DALN 2.41%
  • PTN N/A
  • EPS Growth
  • DALN N/A
  • PTN N/A
  • EPS
  • DALN N/A
  • PTN N/A
  • Revenue
  • DALN $128,286,000.00
  • PTN $2,384,113.00
  • Revenue This Year
  • DALN N/A
  • PTN N/A
  • Revenue Next Year
  • DALN N/A
  • PTN N/A
  • P/E Ratio
  • DALN N/A
  • PTN N/A
  • Revenue Growth
  • DALN N/A
  • PTN N/A
  • 52 Week Low
  • DALN $2.98
  • PTN $0.68
  • 52 Week High
  • DALN $6.99
  • PTN $5.65
  • Technical
  • Relative Strength Index (RSI)
  • DALN 67.81
  • PTN 51.82
  • Support Level
  • DALN $4.78
  • PTN $0.82
  • Resistance Level
  • DALN $4.74
  • PTN $0.99
  • Average True Range (ATR)
  • DALN 0.46
  • PTN 0.12
  • MACD
  • DALN 0.16
  • PTN -0.00
  • Stochastic Oscillator
  • DALN 86.74
  • PTN 55.15

About DALN DallasNews Corporation Series A

DallasNews Corp is a local news and information publishing company in Texas with commercial printing, distribution, and direct mail capabilities, as well as a presence in emerging media and digital marketing.

About PTN Palatin Technologies Inc.

Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.

Share on Social Networks: